In recent years, China has become a global leader in oncology and immunology innovation and a key player in the commercial market for multinational pharma, yet it remains a persistent CI blind spot. Secondary data can be hard to access, as early clinical signals are often buried in China-based platforms and investigator-led trials. Robust primary intelligence can be challenging to gather due to language and cultural barriers. This leaves many Western CI teams exposed to delayed insights and reactive decision-making...even if your organization has a presence in China.
Standard global frameworks fail to capture the realities of the China market, including unique access dynamics, rapid regulatory evolution and an intensifying Western race to license or acquire breakthrough assets, all set against shifting geopolitical pressures.
This session sets out a practical framework to move China from a regional afterthought to a central pillar of global CI capability, actively driving insights and strategic decisions.
